Eisai Inc. to Host Scientific Day on June 29, 2016 in New York City

WOODCLIFF LAKE, N.J., June 22, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it will host a Scientific Day on June 29, 2016 from 9:00 a.m. EDT to 12:45 p.m. EDT in New York City, and will be simultaneously streamed as a webcast.

Eisai logo.

The 2016 Eisai Scientific Day will focus on the company's therapeutics pipeline in both neurology and oncology within the framework of its "Ricchi" philosophy. In Japanese, "Ricchi" is a place where the landscape is clear, a place far away from the crowds, where one would build a home.  Eisai's "Ricchi" involves understanding the unmet needs of patients with some of the hardest-to-treat medical conditions, challenging the innovation boundaries of new medicines toward preventive and curative therapies, and finding new treatment solutions. Eisai is deeply committed to its human health care (hhc) mission and finding "total patient care" solutions.

Haruo Naito, Representative Corporate Officer & CEO, Eisai Co., Ltd.; Ivan Cheung, President, Neurology Business Group and Chairman & CEO, Eisai Inc.; Terushige Iike, President, Oncology Business Group and a host of the company's global scientific leaders will provide insight into Eisai's emerging pipeline and unique approach to discovery and development. Presentations will concentrate on Alzheimer's and dementia-related diseases (neurology) and cancer (oncology) as strategically important areas identified in the company's recently issued "E-Way 2025" business plan. They will also cover Eisai's synergistic collaborations across academia and the industry to further support R&D innovation.

Eisai has a worldwide discovery and development network that includes: Tsukuba Research Laboratories in Japan, which has advanced novel small-molecule drug discoveries in both fields of neurology and oncology; KAN Research Institute in Japan, which is committed to integrated cell biology in neurology; H3 Biomedicine with a focus on cancer genomics located in Cambridge, Mass.; Eisai Andover innovative Medicines (AiM) Institute with a focus on neuro-inflammation and immuno-genetics driven drug discovery in Andover, Mass.; and Morphotek located in Exton, Pa. with an expertise in developing antibodies.

A webcast will be available on the day of the 2016 Eisai Scientific Day (June 29) in the "Investors" section under "Presentations" on the Eisai website at www.eisai.com. A replay of the presentation will be available for 120 days following the event. To ensure a timely connection, users should register at least 15 minutes prior to the scheduled start.

To RSVP to attend this event in person, please contact Janet Cushey at Argot Partners at janet@argotpartners.com.

About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, manufacturing and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at http://us.eisai.com/

About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology. 

For more information about Eisai Co., Ltd., please visit http://www.eisai.com/

Media Inquiries

Investor Inquiries

Patricia Councill

Ivor Macleod

Eisai Inc.

Eisai Inc.

201-746-2139

201-746-2660

Logo - http://photos.prnewswire.com/prnh/20120413/MM87168LOGO

SOURCE Eisai Inc.

Type Press Release

Date Released June 22, 2016

RECENT RELEASES
Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields